| Audience | Patients, caregivers, clinicians, and cannabis-science readers interested in cocaine use disorder treatment in people with co-occurring opioid abuse or dependence |
| Primary Topic | the association between THC-positive and cocaine-positive urine tests during cocaine use disorder treatment |
| Source | Read the full source |
Cannabis and Cocaine Use During Treatment: What Urine Testing Found
A secondary analysis of 301 participants in a medication trial found that THC-positive urine tests were associated with higher odds of cocaine-positive tests during eight weeks of treatment. The result supports careful assessment of polysubstance use, but it does not prove that cannabis caused cocaine use or that stopping cannabis would improve cocaine outcomes.
| Study Type | Secondary observational analysis of a previously reported double-blind randomized medication trial |
| Population | 301 adults meeting criteria for opioid abuse or dependence during cocaine use disorder treatment |
| Participant Profile | Mean age 46 years; 78.4% male, 89.7% non-Hispanic, and 66.5% African American |
| Parent Trial | CTN0048, with extended-release naltrexone plus placebo, 4 mg/day, or 16 mg/day buprenorphine |
| Observation Period | Eight weeks with 25 urine-testing time points |
| Exposure | THC-positive urine drug screen |
| Outcome | Cocaine-positive urine drug screen |
| Main Association | OR 1.47; 95% CI 1.21 to 1.79 |
| Interpretive Boundary | Cannabis exposure was not randomized and the analysis did not test cannabis cessation |
| Journal | Addictive Behaviors |
| Published | July 29, 2026 |
| PMID / DOI | 42561565 / 10.1016/j.addbeh.2026.108817 |
| Conflict Statement | The authors reported no known competing financial interests or personal relationships |
| Major Limitation | Secondary analysis of an older trial in a selected, predominantly male population with co-occurring opioid problems |
Investigators reanalyzed repeated urine samples from 301 participants in CTN0048, a medication trial involving extended-release naltrexone and three buprenorphine conditions.
The new question was observational: whether a THC-positive urine test was associated with the odds of a cocaine-positive urine test across 25 time points during eight weeks of treatment.
THC-positive samples were associated with 47% higher odds of a cocaine-positive sample, with an odds ratio of 1.47 and a 95% confidence interval from 1.21 to 1.79.
Repeated biological testing is a strength because it does not rely only on recall. Still, co-occurrence does not identify which behavior came first or why the two patterns clustered.
Participants were not randomly assigned to use or avoid cannabis. Shared severity, environment, treatment engagement, psychiatric symptoms, social factors, or other unmeasured differences could contribute to both urine-test results.
The study therefore cannot show that THC exposure caused cocaine use, that cocaine use caused cannabis use, or that reducing cannabis would reduce cocaine use.
A THC-positive result can reasonably prompt a nonjudgmental discussion of frequency, motives, impairment, withdrawal, product potency, and how cannabis use fits within the patient’s broader treatment goals.
Counseling should remain individualized. The paper supports assessing both substances, not presenting cannabis cessation as a proven cocaine-use intervention.
The cohort was selected for a trial involving cocaine dependence and co-occurring opioid abuse or dependence. Most participants were male, non-Hispanic, and African American, and the parent trial used DSM-IV criteria.
Results may not generalize to people using cannabis without cocaine, to current treatment settings, or to populations with different demographic and clinical characteristics.
Polysubstance use is often better understood as a pattern shaped by availability, reinforcement, coping, psychiatric symptoms, and social context than as a simple one-drug-causes-another sequence.
The clinical value of this analysis is its reminder to assess cannabis use within the full substance-use picture while preserving uncertainty about cause and treatment effect.
The association is clinically relevant, but it should not be converted into a causal warning. A urine-test pattern can identify a conversation that needs to happen without deciding the answer in advance.
For treatment planning, I would use this result to ask better questions about both substances, define the patient’s goals, and measure change over time. I would not promise that changing cannabis use alone will change cocaine outcomes.
How to Interpret This The Association Between Thc-Positive And Cocaine-Positive Urine Tests During Cocaine Use Disorder Treatment Evidence Without Overstating It
A useful evidence report should let the signal breathe without inflating it.
The right question is not whether the paper is positive or negative, but what kind of decision it can responsibly support.
A Four-Step Reading Frame
Evidence type
Start by identifying whether the paper is a randomized trial, review, meta-analysis, observational study, or protocol.
Population
Ask whether the studied population matches the patient or clinical scenario involving cocaine use disorder treatment in people with co-occurring opioid abuse or dependence.
Outcome meaning
Look at what actually changed, how it was measured, and whether the change would matter in daily life.
Safety and uncertainty
Read limitations and adverse effects as part of the result, not as a footnote.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.
A Signal Worth Discussing, Not Self-Prescribing
For patients interested in the association between THC-positive and cocaine-positive urine tests during cocaine use disorder treatment, the paper creates a reasonable conversation starter but not a do-it-yourself treatment plan.
In this case, the key is to keep cocaine use disorder treatment in people with co-occurring opioid abuse or dependence in view while avoiding claims the study did not test.
Useful Evidence With Practical Gaps
Clinicians can use the paper to discuss cocaine use disorder treatment in people with co-occurring opioid abuse or dependence, but the evidence still leaves product, dose, monitoring, and patient-selection questions open.
In this case, the key is to keep cocaine use disorder treatment in people with co-occurring opioid abuse or dependence in view while avoiding claims the study did not test.
Small Evidence Bases Can Look Larger in Review Form
Systematic reviews can make a field feel mature even when the underlying trials remain few, short, or heterogeneous.
In this case, the key is to keep cocaine use disorder treatment in people with co-occurring opioid abuse or dependence in view while avoiding claims the study did not test.
Outcome Measures Do Not Answer Every Bedside Question
The paper reports measurable outcomes, but patients also need information about durability, adverse effects, interactions, and real-world use.
In this case, the key is to keep cocaine use disorder treatment in people with co-occurring opioid abuse or dependence in view while avoiding claims the study did not test.
A Step Forward, Not the Final Word
This paper advances the conversation by gathering available evidence, but it also highlights how much cannabinoid research still depends on small or uneven studies.
In this case, the key is to keep cocaine use disorder treatment in people with co-occurring opioid abuse or dependence in view while avoiding claims the study did not test.
Monitoring Matters
If cannabinoids are considered clinically, monitoring should include symptom response, side effects, sedation or impairment, medication interactions, and patient goals.
In this case, the key is to keep cocaine use disorder treatment in people with co-occurring opioid abuse or dependence in view while avoiding claims the study did not test.
What Better Evidence Would Need
Stronger trials should define formulation, dose, comparator, duration, responder profiles, and safety monitoring before broad claims are made.
In this case, the key is to keep cocaine use disorder treatment in people with co-occurring opioid abuse or dependence in view while avoiding claims the study did not test.
Access Should Not Outrun Evidence Quality
Patients deserve access to careful information, but public messaging should not make early evidence sound settled.
In this case, the key is to keep cocaine use disorder treatment in people with co-occurring opioid abuse or dependence in view while avoiding claims the study did not test.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
Does this study prove that the association between THC-positive and cocaine-positive urine tests during cocaine use disorder treatment works?
No. It supports a clinically interesting signal, but proof requires larger, better-controlled, and more specific trials.
Is this enough evidence to change treatment on its own?
No. It can inform a clinical conversation, but it should not replace individualized medical judgment or established care.
Why does study design matter here?
Design affects how confidently readers can separate a true treatment effect from bias, placebo response, measurement choices, and patient selection.
What is the biggest limitation?
The biggest limitation is that the available studies are relatively small, heterogeneous, and not long enough to answer every practical safety question.
Does this apply to every cannabis or CBD product?
No. Products differ by cannabinoid content, dose, route, purity, and testing standards, so one paper cannot validate every product.
What should patients ask their clinician?
Patients should ask how the evidence relates to their own cocaine use disorder treatment in people with co-occurring opioid abuse or dependence, medication list, risks, goals, and monitoring plan.
Are side effects still important if the findings are positive?
Yes. Benefit and risk have to be interpreted together, especially for sedation, impairment, interactions, and vulnerable populations.
Why include this as a full CED report?
The paper is recent, clinically relevant, and evidence-based enough to deserve careful standalone interpretation rather than a short mention.
What would stronger research add?
Stronger research would clarify formulation, dose, duration, responder profiles, active comparators, long-term outcomes, and safety monitoring.
What is the practical takeaway?
The practical takeaway is cautious interest: the signal is worth knowing, but the clinical decision still has to be individualized.
